Business Description
Shanghai Junshi Biosciences Co Ltd
ISIN : CNE100003FF7
Share Class Description:
HKSE:01877: Class HCompare
Compare
Traded in other countries / regions
688180.China01877.Hong Kong8SJ.GermanySHJBF.USA IPO Date
2018-12-24Description
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.11 | |||||
| Equity-to-Asset | 0.63 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | -1.44 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | 4.43 | |||||
| Beneish M-Score | -3.87 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 17.1 | |||||
| 3-Year EBITDA Growth Rate | -43 | |||||
| 3-Year EPS without NRI Growth Rate | -39.7 | |||||
| 3-Year FCF Growth Rate | 3.2 | |||||
| 3-Year Book Growth Rate | 36.5 | |||||
| Future 3-5Y Total Revenue Growth Rate | 28.59 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.94 | |||||
| 9-Day RSI | 63.54 | |||||
| 14-Day RSI | 55.11 | |||||
| 6-1 Month Momentum % | -44.8 | |||||
| 12-1 Month Momentum % | -66.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.24 | |||||
| Quick Ratio | 2.02 | |||||
| Cash Ratio | 1.53 | |||||
| Days Sales Outstanding | 177.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 | |||||
| Shareholder Yield % | -1.71 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -160.56 | |||||
| Net Margin % | -146.33 | |||||
| ROE % | -14.32 | |||||
| ROA % | -10.09 | |||||
| ROIC % | -18.15 | |||||
| ROC (Joel Greenblatt) % | -34.07 | |||||
| ROCE % | -12.47 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.36 | |||||
| PB Ratio | 1.35 | |||||
| Price-to-Tangible-Book | 1.38 | |||||
| EV-to-EBIT | -16.81 | |||||
| EV-to-Forward-EBIT | -15.81 | |||||
| EV-to-EBITDA | -16.81 | |||||
| EV-to-Forward-EBITDA | -17.65 | |||||
| EV-to-Revenue | 25.2 | |||||
| EV-to-Forward-Revenue | 15.26 | |||||
| EV-to-FCF | -9.41 | |||||
| Price-to-Net-Current-Asset-Value | 7.11 | |||||
| Earnings Yield (Greenblatt) % | -5.95 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Shanghai Junshi Biosciences Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 904.743 | ||
| EPS (TTM) (HK$) | -2.505 | ||
| Beta | 0.68 | ||
| Volatility % | 61 | ||
| 14-Day RSI | 55.11 | ||
| 14-Day ATR (HK$) | 0.573449 | ||
| 20-Day SMA (HK$) | 10.0025 | ||
| 12-1 Month Momentum % | -66.9 | ||
| 52-Week Range (HK$) | 9.17 - 31.1 | ||
| Shares Outstanding (Mil) | 985.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Junshi Biosciences Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Shanghai Junshi Biosciences Co Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Shanghai Junshi Biosciences Co Ltd Frequently Asked Questions
What is Shanghai Junshi Biosciences Co Ltd(HKSE:01877)'s stock price today?
The current price of HKSE:01877 is HK$10.74. The 52 week high of HKSE:01877 is HK$31.10 and 52 week low is HK$9.17.
When is next earnings date of Shanghai Junshi Biosciences Co Ltd(HKSE:01877)?
The next earnings date of Shanghai Junshi Biosciences Co Ltd(HKSE:01877) is 2024-04-29 Est..
Does Shanghai Junshi Biosciences Co Ltd(HKSE:01877) pay dividends? If so, how much?
Shanghai Junshi Biosciences Co Ltd(HKSE:01877) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers